Clinical Efficacy of Spray-Type Nasal Allergen Blocker as Adjuvant Treatment for Pediatric Allergic Rhinitis.

OBJECTIVE

To evaluate the clinical efficacy of Spray-Type Nasal Allergen Blocker as an adjuvant therapy for pediatric allergic rhinitis (AR).

METHODS

Eighty-two pediatric AR patients aged 4 to 14 years were included in this retrospective study and divided into 2 groups based on the treatments documented in their medical records: one treated with Mometasone Furoate Aqueous Nasal Spray (n = 38) and the other with a combination of a Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray (n = 44).

RESULTS

After 4 weeks of treatment, the total effective rate, the serum levels of IFN-γ, TGF-β, nasal ventilation area, ciliary movement rate, and pediatric Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores were higher in the Combination group than in Mometasone group, while the Total Nasal Symptom Score (TNSS) and nasal resistance were lower in the Combination group (P < .05).

CONCLUSION

Combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray exhibits promising results in the treatment of pediatric AR compared to Mometasone Furoate Aqueous Nasal Spray alone.